Advertisement|Remove ads.

President Donald Trump is reportedly assembling a high-profile technology advisory council, enlisting some of the top executives in the tech world to guide policy on artificial intelligence and other emerging technologies.
According to The Wall Street Journal report, Meta Platforms Inc. (META) CEO Mark Zuckerberg, Oracle Corp. (ORCL) executive chairman Larry Ellison, and Nvidia Corp. (NVDA) CEO Jensen Huang are among the prominent figures set to join the council
“The United States has the opportunity to lead the world in AI. I’m honored to join the President’s council and work with other industry leaders to help make this happen.”
-Mark Zuckerberg, CEO, Meta Platforms
The newly formed President’s Council of Advisors on Science and Technology (PCAST) will be co-chaired by David Sacks, a former White House AI and cryptocurrency advisor, and Michael Kratsios, who had previously served as a technology advisor.
The initial roster of 13 members also includes Google co-founder Sergey Brin, with the council potentially expanding to 24 members under an executive order. The council will provide guidance on science, innovation, and policy, offering analysis, gathering stakeholder input, and supporting national initiatives in technology and research.
During his second term, Trump has prioritized creating a regulatory framework designed to bolster U.S. leadership in AI.
On Friday, the Trump administration introduced an artificial intelligence policy designed to unify federal oversight, while calling on Congress to override what it described as excessive constraints created by state-level regulations.
“The Trump Administration is committed to winning the AI race to usher in a new era of human flourishing, economic competitiveness, and national security for the American people,” the White House said.
According to the report, many of the selected executives have previously supported Trump’s initiatives, including donations from Meta and personal contributions from Huang to White House events.
Also See: SRPT Stock Rallies After Promising Early Results For RNA Therapies Targeting Rare Muscle Diseases
For updates and corrections, email newsroom[at]stocktwits[dot]com.